See more : Old Mutual Limited (OMU.L) Income Statement Analysis – Financial Results
Complete financial analysis of MedX Health Corp (MDXHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedX Health Corp, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Solid Year Co., Ltd. (6737.TWO) Income Statement Analysis – Financial Results
- The Ogaki Kyoritsu Bank, Ltd. (8361.T) Income Statement Analysis – Financial Results
- American Metals Recovery and Recycling Inc. (AMRR) Income Statement Analysis – Financial Results
- Premier Development & Investment, Inc. (PDIV) Income Statement Analysis – Financial Results
- Story-I Limited (SRY.AX) Income Statement Analysis – Financial Results
MedX Health Corp (MDXHF)
About MedX Health Corp
MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 456.09K | 510.61K | 563.10K | 530.07K | 860.25K | 1.09M | 1.09M | 817.06K | 1.17M | 877.73K | 579.65K | 728.29K | 872.58K | 657.36K | 451.38K | 1.15M | 1.06M | 2.60M | 2.93M | 2.74M | 1.32M |
| Cost of Revenue | 270.46K | 270.66K | 273.67K | 261.96K | 380.43K | 398.24K | 478.75K | 379.23K | 509.79K | 390.72K | 269.80K | 299.58K | 381.84K | 244.47K | 689.00K | 315.08K | 371.52K | 571.82K | 656.17K | 503.11K | 211.66K |
| Gross Profit | 185.63K | 239.95K | 289.44K | 268.11K | 479.82K | 689.19K | 614.49K | 437.83K | 661.63K | 487.02K | 309.85K | 428.71K | 490.74K | 412.89K | -237.63K | 834.39K | 684.27K | 2.02M | 2.28M | 2.24M | 1.11M |
| Gross Profit Ratio | 40.70% | 46.99% | 51.40% | 50.58% | 55.78% | 63.38% | 56.21% | 53.59% | 56.48% | 55.49% | 53.45% | 58.87% | 56.24% | 62.81% | -52.65% | 72.59% | 64.81% | 77.98% | 77.62% | 81.65% | 83.97% |
| Research & Development | 586.08K | 681.80K | 995.36K | 431.16K | 535.46K | 880.77K | 182.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 121.79K | 286.50K | 138.75K | 16.80K | 22.41K | 105.18K | 164.58K |
| General & Administrative | 1.66M | 1.80M | 2.08M | 2.79M | 2.94M | 3.80M | 1.83M | 1.56M | 1.30M | 1.00M | 1.20M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 554.56K | 1.15M | 1.47M | 585.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.21M | 2.94M | 3.55M | 2.79M | 2.94M | 3.80M | 1.83M | 1.56M | 1.30M | 1.00M | 1.20M | 1.71M | 1.28M | 1.30M | 2.29M | 3.18M | 2.62M | 3.00M | 3.69M | 2.23M | 1.32M |
| Other Expenses | -2.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 185.63K | 4.11M | 4.85M | 3.30M | 3.61M | 4.77M | 2.11M | 1.66M | 1.34M | 1.04M | 1.23M | 1.75M | 1.34M | 1.41M | 2.32M | 3.52M | 2.80M | 3.41M | 4.03M | 2.56M | 2.04M |
| Cost & Expenses | 3.48M | 4.38M | 5.13M | 3.56M | 3.99M | 5.17M | 2.59M | 2.04M | 1.85M | 1.43M | 1.50M | 2.05M | 1.73M | 1.65M | 3.00M | 3.83M | 3.17M | 3.99M | 4.68M | 3.07M | 2.25M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.15M | 1.27M | 777.61K | 58.17K | 125.03K | 101.89K | 115.62K | 66.82K | 28.08K | 10.36K | 113.05K | 162.10K | 111.14K | 0.00 | 907.00 | 74.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 51.83K | 51.69K | 51.81K | 79.45K | 136.25K | 100.82K | 101.59K | 104.86K | 44.22K | 40.58K | 37.45K | 42.29K | 68.33K | 26.93K | 33.75K | 44.19K | 441.85K | 157.85K | 145.03K | 123.19K | 86.52K |
| EBITDA | -2.38M | -3.82M | -4.54M | -2.95M | -3.02M | -3.98M | -1.39M | -1.16M | -637.39K | -514.97K | -885.43K | -1.28M | -688.63K | -965.65K | -2.52M | -2.64M | -1.67M | -1.23M | -1.60M | -202.55K | -847.27K |
| EBITDA Ratio | -521.55% | -747.48% | -801.09% | -556.53% | -348.06% | -366.37% | -127.38% | -136.50% | -54.41% | -58.67% | -152.75% | -175.71% | -89.97% | -146.90% | -558.13% | -229.78% | -158.55% | -41.23% | -54.73% | -7.39% | -64.19% |
| Operating Income | -3.03M | -3.87M | -4.56M | -3.03M | -3.13M | -4.08M | -1.49M | -1.22M | -681.61K | -555.55K | -922.89K | -1.32M | -853.36K | -992.57K | -2.55M | -2.69M | -2.12M | -1.23M | -1.75M | -325.73K | -933.79K |
| Operating Income Ratio | -663.25% | -757.61% | -810.29% | -571.52% | -363.90% | -375.64% | -136.67% | -149.33% | -58.19% | -63.29% | -159.22% | -181.51% | -97.80% | -150.99% | -565.60% | -233.62% | -200.40% | -47.31% | -59.67% | -11.88% | -70.74% |
| Total Other Income/Expenses | -1.56M | -1.27M | -760.79K | -170.06K | -145.91K | -101.79K | -110.27K | -115.14K | 182.36K | 350.97K | -969.46K | 782.72K | -185.27K | 0.00 | 0.00 | 0.00 | 24.67K | -161.52K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.58M | -5.13M | -5.32M | -3.20M | -3.28M | -4.19M | -1.60M | -1.34M | -499.25K | -204.58K | -1.89M | -539.22K | -868.09K | 0.00 | 0.00 | 0.00 | -2.09M | -1.39M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,004.31% | -1,005.41% | -945.40% | -603.60% | -380.86% | -385.00% | -146.76% | -163.43% | -42.62% | -23.31% | -326.47% | -74.04% | -99.48% | 0.00% | 0.00% | 0.00% | -198.07% | -53.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.27M | 777.61K | 58.17K | 125.03K | 101.89K | 115.62K | 66.82K | 28.08K | 10.36K | 113.05K | 162.10K | 0.00 | 0.00 | 6.01K | 81.32K | 38.46K | 169.01K | 18.60K | 74.92K | 509.05K |
| Net Income | -4.58M | -5.13M | -5.32M | -3.20M | -3.28M | -4.19M | -1.60M | -1.34M | -499.25K | -204.58K | -1.89M | -539.22K | -868.09K | -992.57K | -2.56M | -2.77M | -2.10M | -1.56M | -1.77M | -400.66K | -1.44M |
| Net Income Ratio | -1,004.31% | -1,005.41% | -945.40% | -603.60% | -380.86% | -385.00% | -146.76% | -163.43% | -42.62% | -23.31% | -326.47% | -74.04% | -99.48% | -150.99% | -566.94% | -240.69% | -198.53% | -60.04% | -60.31% | -14.61% | -109.31% |
| EPS | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | 0.00 | -0.04 | -0.01 | -0.02 | -0.03 | -0.09 | -0.11 | -0.14 | -0.10 | -0.12 | -0.03 | -0.13 |
| EPS Diluted | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | 0.00 | -0.04 | -0.01 | -0.02 | -0.03 | -0.09 | -0.11 | -0.14 | -0.10 | -0.12 | -0.03 | -0.13 |
| Weighted Avg Shares Out | 196.71M | 183.74M | 180.18M | 166.56M | 140.19M | 130.35M | 103.75M | 83.63M | 70.71M | 67.40M | 42.76M | 36.51M | 34.98M | 30.27M | 27.02M | 24.10M | 15.06M | 15.04M | 14.63M | 12.12M | 10.80M |
| Weighted Avg Shares Out (Dil) | 196.71M | 183.74M | 180.18M | 166.56M | 140.19M | 130.35M | 103.75M | 83.63M | 70.71M | 67.40M | 42.76M | 36.51M | 34.98M | 30.27M | 27.02M | 24.10M | 15.06M | 15.04M | 14.63M | 12.12M | 10.80M |
MDXH Stock: 38.06% Fall Explained
The stock price of MDxHealth SA (MDXH) fell by 38.06% in the most recent trading session. This is why.
MedX Health says its SIAscopy/DermSecure products show significant promise as it reports Q1 results
MedX Health Corp. (TSX-V:MDX) has said its SIAscopy and DermSecure products have shown significant promise with the signing of commercial agreements for their deployment, which should provide a solid revenue base for the rest of the year. The paid pilot-to-commercial agreements consist...
MedX Health says revenue in 2021 rose from previous year despite tough conditions
MedX Health Corp has released its results for the financial year ended December 31, 2021, showing revenue came in at $563,101, higher than the $530,066 recorded in 2020. Revenues from sales of therapeutic laser products were 16% higher than the prior-year while revenues from...
MedX signs distribution agreement with Vitamed Biomedical to launch its teledermatology screening platform in Italy
MedX Health Corp. (TSX-V:MDX) said it has signed a commercial distribution agreement with Vitamed Biomedical s.r.l. to launch its teledermatology screening platform in Italy following the conclusion of a successful pilot project.
MedX Health appoints healthcare veteran Naman Demaghlatrous as its new CEO
MedX Health Corp. (TSX-V:MDX) has announced the appointment of Naman Demaghlatrous as the company's new president and CEO, effective immediately. MedX said Demaghlatrous has more than 20 years of healthcare and pharmaceutical industry experience, having served in senior roles with...
MedX Health closes first tranche of the non-brokered private placement with the issuance of 20 convertible loan notes which raised a total of $1M
MedX Health Corp said it has closed the first tranche of the non-brokered private placement it announced on March 1, 2022, with the issuance of 20 convertible loan notes which raised a total of $1 million. The private placement to accredited investors...
MedX Health strikes agreement with Health Partners to launch tele dermatology screening platform in the UK
MedX Health Corp, a leader in tele dermatology, has announced a Memorandum of Understanding (MOU) and the launch of a new commercialization pilot project with Health Partners (OH) Limited, a privately owned corporate health and primary care services company in...
MedX Health proposes non-brokered private placement of up to 80 Convertible Loan Notes to raise up to $4 million
MedX Health Corp said it is proposing a non-brokered private placement to accredited investors of up to $4 million by the issuance of up to 80 Convertible Loan Notes, each with a face value of $50,000. The convertible notes will...
MedX Health is expanding North American operations with doctor-pharmacy rollout
As MedX Health Corp heads into 2022, the global leader in teledermatology has launched the next step in its business plan for North America. The company is now offering its life-saving skin-screening services in blended physician and pharmacy clinic settings...
MedX Health launches two more screening services locations in Ottawa
MedX Health Corp announced the launch of two locations for MediX Screening Services in Ottawa, Canada. The company said that both locations will now offer MedX scanning services and accept walk-in patients.
Source: https://incomestatements.info
Category: Stock Reports